Dr Dmitry Bulavin said, Our focus on Wip1 phosphatase for over ten years has revealed several key features of this molecule. Our current results strongly support the use of an anti-Wip1 drug for cancer treatment to be able to reduce a high regularity of mutations in the genome, which is one of the main drivers of tumour relapses. Prof Hong Wan Jin, Executive Director of IMCB, said, Dmitry has been the pioneering driver in the mechanistic research of Wip1 phosphatase, which discovery is certainly monumental in providing novel understanding on the part of Wip1 in tumor at the genomic and systems levels. I am self-confident that his group at IMCB can further their work in cancer study to offer new techniques for potential drugs against this target.Pullman, M.B., B.S., Ph.D., F.R.A.C.P.: Ecallantide for the treating Acute Attacks in Hereditary Angioedema Hereditary angioedema is an autosomal dominant disorder with an estimated prevalence which range from 1 case in 10,000 to 1 1 case in 50,000 persons.1-3 Patients with hereditary angioedema have intermittent acute attacks of edema involving the larynx, oropharynx, encounter, gastrointestinal mucosa, extremities, or genitalia.4 Episodes occur unpredictably and could persist for 2 to 5 days.5,6 Gastrointestinal attacks could cause incapacitating colic, vomiting, and diarrhea and may result in unnecessary abdominal surgery. Laryngeal attacks may be life-threatening due to the prospect of airway obstruction.5,7 Attacks do not typically react to antihistamines, corticosteroids, or epinephrine.8 The C1 esterase inhibitor is a significant inhibitor of plasma kallikrein and coagulation factor XIIa.9-11 Decreased degrees of C1 esterase inhibitor in sufferers with hereditary angioedema result in unrestrained plasma kallikrein activity, leading to elevated degrees of bradykinin.9,12,13 Bradykinin is a potent vasodilator that raises capillary endothelial permeability, evoking the localized edema and painful swelling that are the hallmarks of an acute strike of angioedema in sufferers with this disease.9 Although approved therapies for treatment of acute attacks in patients with hereditary angioedema have already been available to patients beyond your United States for several years,14 approved, disease-specific therapies have just become available in the usa recently.8,17 Ecallantide is a recombinant protein synthesized in the yeast Pichia pastoris.18-20 Ecallantide is a powerful and specific inhibitor of plasma kallikrein.8,18-20 In phase 2 trials, symptoms of angioedema improved within 4 hours after treatment with ecallantide.18,21 The Evaluation of DX-88’s Results in Mitigating Angioedema 3 trial was a randomized, placebo-controlled, phase 3 evaluation of ecallantide for the treatment of severe attacks of angioedema in sufferers with hereditary angioedema.